NBTX:NASDAQNanobiotix S.A. analysis
Data as of Oct 14, 2026 - not real-time
- Latest price
- $21.49
- Risk: high
- 9/10High risk
Summary
Nanobiotix S.A. trades at $21.49, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Over a rolling month the price has lost 47.1%. Relative strength is 21.8 — oversold — and the MACD signal is bearish. Watch $21.22 as support and $36.10 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 150.4% above today's level. Revenue is contracting at 79.2%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 64.2%, a beta of 1.66 and a maximum drawdown of 61.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 150.4% above today's level. Revenue is contracting at 79.2%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 64.2%, a beta of 1.66 and a maximum drawdown of 61.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top market events
- PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 GLOBE NEWSWIRE -- NANOBIOTIX Euronext: NANO - NASDAQ: NBTX - the...
- Nanobiotix S.A. NASDAQ:NBTX reported September 14 results from all 24 patients in the dose-escalation and expansion...
- Nanobiotix, a late-stage clinical biotech company, named Arnd Christ as CFO effective October 1, 2026.
Market outlook
Short term
< 1 yearNeutral
Model confidence1/101 out of 10
Key factors
- RSI at 21.8 signals oversold conditions
- Trading below the 200-day average of 33.44
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- RSI at 21.8 signals oversold conditions
- Trading below the 200-day average of 33.44
- Analyst targets imply +150.4% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +150.4% versus the current price
- Revenue contracting at -79.2%
- Negative free cash flow
Key metrics
Financial health
Revenue Growth-79.20%
P/E Ratio-129.0
ROA-21.34%
P/B Ratio-29.3
Op. Cash Flow$-34186000
Free Cash Flow$-32782250
Industry P/E30.3
Technical analysis
TrendNeutral
RSI21.8
Support$21.22
Resistance$36.10
MA 20$29.52
MA 50$35.70
MA 200$33.44
MACDBearish
VolumeIncreasing
Fear & Greed Index94.2
Valuation
Target Price$53.81
Upside/Downside150.40%
GradeFair
TypeBlend
Risk assessment
Beta1.66
Volatility64.21%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.